Report Detail
Global Cancer Janus Kinase Inhibitors Market Insights, Forecast to 2025
- RnM2896734 |
- 19 June, 2019 |
- Global |
- 121 Pages |
- QYResearch |
- Pharma & Healthcare
Cancer Janus Kinase Inhibitors
The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revolutionized the outlook of the future of cancer management. Amongst both of the modern therapies, targeted therapies have shown an impressive growth in a very short duration of time. The targeted therapies developed rapidly and gained much importance in the global market for cancer therapeutics due to their advantages over the conventional therapies. Targeted therapies are safer and more efficient approach for managing cancer. The only drawback for targeted therapies was that only a few targets were available for developing cancer therapeutics. The high efficacy of targeted therapeutics for cancer raised the demand for identifying new targets.
The global Cancer Janus Kinase Inhibitors market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cancer Janus Kinase Inhibitors market based on company, product type, end user and key regions.
This report studies the global market size of Cancer Janus Kinase Inhibitors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer Janus Kinase Inhibitors in these regions.
This research report categorizes the global Cancer Janus Kinase Inhibitors market by top players/brands, region, type and end user. This report also studies the global Cancer Janus Kinase Inhibitors market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Abbott Laboratories
Asana Biosciences
Astra Zeneca
Celon Pharmaceuticals
Dynamic Pharma
Eli Lilly
Gilead Sciences
Hanmi Pharmaceuticals
Incyte
Kyowa Hakko
Moleculin
Pfizer
PIQUR Therapeutics
Portola Pharmaceuticals
S-BIO
Market size by Product
Ruxolitinib
Momelotinib
Lestaurtinib
Pacritinib
Market size by End User
Hospitals
Ambulatory Surgical Centers
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Cancer Janus Kinase Inhibitors market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Cancer Janus Kinase Inhibitors market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Cancer Janus Kinase Inhibitors companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Cancer Janus Kinase Inhibitors submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Cancer Janus Kinase Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cancer Janus Kinase Inhibitors market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Cancer Janus Kinase Inhibitors Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Cancer Janus Kinase Inhibitors Market Size Growth Rate by Product
- 1.4.2 Ruxolitinib
- 1.4.3 Momelotinib
- 1.4.4 Lestaurtinib
- 1.4.5 Pacritinib
- 1.5 Market by End User
- 1.5.1 Global Cancer Janus Kinase Inhibitors Market Size Growth Rate by End User
- 1.5.2 Hospitals
- 1.5.3 Ambulatory Surgical Centers
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Cancer Janus Kinase Inhibitors Market Size
- 2.1.1 Global Cancer Janus Kinase Inhibitors Revenue 2014-2025
- 2.1.2 Global Cancer Janus Kinase Inhibitors Sales 2014-2025
- 2.2 Cancer Janus Kinase Inhibitors Growth Rate by Regions
- 2.2.1 Global Cancer Janus Kinase Inhibitors Sales by Regions
- 2.2.2 Global Cancer Janus Kinase Inhibitors Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Cancer Janus Kinase Inhibitors Sales by Manufacturers
- 3.1.1 Cancer Janus Kinase Inhibitors Sales by Manufacturers
- 3.1.2 Cancer Janus Kinase Inhibitors Sales Market Share by Manufacturers
- 3.1.3 Global Cancer Janus Kinase Inhibitors Market Concentration Ratio (CR5 and HHI)
- 3.2 Cancer Janus Kinase Inhibitors Revenue by Manufacturers
- 3.2.1 Cancer Janus Kinase Inhibitors Revenue by Manufacturers (2014-2019)
- 3.2.2 Cancer Janus Kinase Inhibitors Revenue Share by Manufacturers (2014-2019)
- 3.3 Cancer Janus Kinase Inhibitors Price by Manufacturers
- 3.4 Cancer Janus Kinase Inhibitors Manufacturing Base Distribution, Product Types
- 3.4.1 Cancer Janus Kinase Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Cancer Janus Kinase Inhibitors Product Type
- 3.4.3 Date of International Manufacturers Enter into Cancer Janus Kinase Inhibitors Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Cancer Janus Kinase Inhibitors Sales by Product
- 4.2 Global Cancer Janus Kinase Inhibitors Revenue by Product
- 4.3 Cancer Janus Kinase Inhibitors Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Cancer Janus Kinase Inhibitors Breakdown Data by End User
6 North America
- 6.1 North America Cancer Janus Kinase Inhibitors by Countries
- 6.1.1 North America Cancer Janus Kinase Inhibitors Sales by Countries
- 6.1.2 North America Cancer Janus Kinase Inhibitors Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Cancer Janus Kinase Inhibitors by Product
- 6.3 North America Cancer Janus Kinase Inhibitors by End User
7 Europe
- 7.1 Europe Cancer Janus Kinase Inhibitors by Countries
- 7.1.1 Europe Cancer Janus Kinase Inhibitors Sales by Countries
- 7.1.2 Europe Cancer Janus Kinase Inhibitors Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Cancer Janus Kinase Inhibitors by Product
- 7.3 Europe Cancer Janus Kinase Inhibitors by End User
8 Asia Pacific
- 8.1 Asia Pacific Cancer Janus Kinase Inhibitors by Countries
- 8.1.1 Asia Pacific Cancer Janus Kinase Inhibitors Sales by Countries
- 8.1.2 Asia Pacific Cancer Janus Kinase Inhibitors Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Cancer Janus Kinase Inhibitors by Product
- 8.3 Asia Pacific Cancer Janus Kinase Inhibitors by End User
9 Central & South America
- 9.1 Central & South America Cancer Janus Kinase Inhibitors by Countries
- 9.1.1 Central & South America Cancer Janus Kinase Inhibitors Sales by Countries
- 9.1.2 Central & South America Cancer Janus Kinase Inhibitors Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Cancer Janus Kinase Inhibitors by Product
- 9.3 Central & South America Cancer Janus Kinase Inhibitors by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Cancer Janus Kinase Inhibitors by Countries
- 10.1.1 Middle East and Africa Cancer Janus Kinase Inhibitors Sales by Countries
- 10.1.2 Middle East and Africa Cancer Janus Kinase Inhibitors Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Cancer Janus Kinase Inhibitors by Product
- 10.3 Middle East and Africa Cancer Janus Kinase Inhibitors by End User
11 Company Profiles
- 11.1 Abbott Laboratories
- 11.1.1 Abbott Laboratories Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Abbott Laboratories Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Abbott Laboratories Cancer Janus Kinase Inhibitors Products Offered
- 11.1.5 Abbott Laboratories Recent Development
- 11.2 Asana Biosciences
- 11.2.1 Asana Biosciences Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Asana Biosciences Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Asana Biosciences Cancer Janus Kinase Inhibitors Products Offered
- 11.2.5 Asana Biosciences Recent Development
- 11.3 Astra Zeneca
- 11.3.1 Astra Zeneca Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Astra Zeneca Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Astra Zeneca Cancer Janus Kinase Inhibitors Products Offered
- 11.3.5 Astra Zeneca Recent Development
- 11.4 Celon Pharmaceuticals
- 11.4.1 Celon Pharmaceuticals Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Celon Pharmaceuticals Cancer Janus Kinase Inhibitors Products Offered
- 11.4.5 Celon Pharmaceuticals Recent Development
- 11.5 Dynamic Pharma
- 11.5.1 Dynamic Pharma Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Dynamic Pharma Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Dynamic Pharma Cancer Janus Kinase Inhibitors Products Offered
- 11.5.5 Dynamic Pharma Recent Development
- 11.6 Eli Lilly
- 11.6.1 Eli Lilly Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Eli Lilly Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Eli Lilly Cancer Janus Kinase Inhibitors Products Offered
- 11.6.5 Eli Lilly Recent Development
- 11.7 Gilead Sciences
- 11.7.1 Gilead Sciences Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Gilead Sciences Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Gilead Sciences Cancer Janus Kinase Inhibitors Products Offered
- 11.7.5 Gilead Sciences Recent Development
- 11.8 Hanmi Pharmaceuticals
- 11.8.1 Hanmi Pharmaceuticals Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Hanmi Pharmaceuticals Cancer Janus Kinase Inhibitors Products Offered
- 11.8.5 Hanmi Pharmaceuticals Recent Development
- 11.9 Incyte
- 11.9.1 Incyte Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Incyte Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Incyte Cancer Janus Kinase Inhibitors Products Offered
- 11.9.5 Incyte Recent Development
- 11.10 Kyowa Hakko
- 11.10.1 Kyowa Hakko Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Kyowa Hakko Cancer Janus Kinase Inhibitors Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Kyowa Hakko Cancer Janus Kinase Inhibitors Products Offered
- 11.10.5 Kyowa Hakko Recent Development
- 11.11 Moleculin
- 11.12 Pfizer
- 11.13 PIQUR Therapeutics
- 11.14 Portola Pharmaceuticals
- 11.15 S-BIO
12 Future Forecast
- 12.1 Cancer Janus Kinase Inhibitors Market Forecast by Regions
- 12.1.1 Global Cancer Janus Kinase Inhibitors Sales Forecast by Regions 2019-2025
- 12.1.2 Global Cancer Janus Kinase Inhibitors Revenue Forecast by Regions 2019-2025
- 12.2 Cancer Janus Kinase Inhibitors Market Forecast by Product
- 12.2.1 Global Cancer Janus Kinase Inhibitors Sales Forecast by Product 2019-2025
- 12.2.2 Global Cancer Janus Kinase Inhibitors Revenue Forecast by Product 2019-2025
- 12.3 Cancer Janus Kinase Inhibitors Market Forecast by End User
- 12.4 North America Cancer Janus Kinase Inhibitors Forecast
- 12.5 Europe Cancer Janus Kinase Inhibitors Forecast
- 12.6 Asia Pacific Cancer Janus Kinase Inhibitors Forecast
- 12.7 Central & South America Cancer Janus Kinase Inhibitors Forecast
- 12.8 Middle East and Africa Cancer Janus Kinase Inhibitors Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Cancer Janus Kinase Inhibitors Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Cancer Janus Kinase Inhibitors . Industry analysis & Market Report on Cancer Janus Kinase Inhibitors is a syndicated market report, published as Global Cancer Janus Kinase Inhibitors Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Cancer Janus Kinase Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
